President And CEO
Medicine
ARCA Biopharma
United States of America
During 2016, we continued to make progress advancing the GENETIC-AF clinical trial evaluating Gencaro as potentially the first genetically-targeted treatment for atrial fibrillation," commented Dr. Michael Bristow, ARCA's President and Chief Executive Officer.
Clinical trials